NYSEHealth CareHealth Care TechnologyS&P MidCap 400
$32.51
-0.67 (-2.02%)
Close of Nov 06, 2026 · end-of-day data
DOCS 8-K filings in 2024
Every material Form 8-K Doximity filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Doximity reported fiscal second-quarter results for the period ended September 30, 2024, with revenue up 20% year-over-year and net income up 44%. The company also updated its full-year fiscal 2025 guidance, with revenue now expected at $535 million to $540 million, which shareholders will want to compare with the prior outlook.
Revenue of $136.8 million, up 20% from $113.6 million a year earlier
Net income of $44.2 million, up from $30.6 million; diluted EPS of $0.22 versus $0.15
Fiscal 2025 guidance: revenue $535 million to $540 million and adjusted EBITDA $274 million to $279 million; fiscal third-quarter revenue guidance of $152 million to $153 million
Restructuring and impairment charge of $2.3 million in the quarter, compared with $7.9 million a year earlier
Doximity reported results for the fiscal 2025 first quarter ended June 30, 2024, with revenue of $126.7 million, up 17% year-over-year, and net income of $41.4 million, up from $28.4 million. The company also issued guidance for the fiscal second quarter and full fiscal 2025, but the filing does not compare that guidance with any prior outlook. Operating cash flow fell 28% to $41.2 million, and the company repurchased $51.2 million of common stock during the quarter.
Revenue of $126.7 million, up 17% from $108.5 million a year earlier
Net income of $41.4 million, up from $28.4 million; diluted EPS of $0.21 versus $0.13
Adjusted EBITDA of $65.9 million, up 42%; operating cash flow of $41.2 million, down 28%
Fiscal 2025 revenue guidance of $514 million to $523 million; fiscal second quarter revenue guidance of $126.5 million to $127.5 million
Doximity reported fiscal fourth-quarter revenue of $118.1 million, up 6% year-over-year, with net income of $40.6 million, up 32%, and adjusted EBITDA of $56.4 million, up 15%. The company also gave fiscal 2025 revenue guidance of $506 million to $518 million and authorized a $500 million share repurchase program, which matters to shareholders because it signals profit growth alongside capital returns.
Q4 revenue of $118.1 million versus $111.0 million; subscription revenue of $112.7 million, up 9%
Fiscal 2024 revenue of $475.4 million, up 13%; net income of $147.6 million, up 31%
Guidance: fiscal Q1 2025 revenue of $119.5 million to $120.5 million; fiscal 2025 revenue of $506 million to $518 million
Board authorized up to $500 million of Class A stock repurchases on May 1, 2024, with no expiration date
Doximity reported fiscal third-quarter results for the quarter ended December 31, 2023, with revenue of $135.3 million, up 17%, net income of $48.0 million, up from $33.5 million, and adjusted EBITDA of $73.3 million, up 32%. The company also updated its fiscal 2024 guidance, with full-year revenue now expected between $473.3 million and $474.3 million, and CEO Jeff Tangney called the quarter a "beat and raise" on both top and bottom lines.
Revenue of $135.3 million, versus $115.3 million a year earlier, an increase of 17%.
Net income of $48.0 million, or $0.24 diluted per share, versus $33.5 million, or $0.16, a year earlier.
Fiscal fourth-quarter guidance: revenue of $115.9 million to $116.9 million and adjusted EBITDA of $50.5 million to $51.5 million.
Fiscal 2024 guidance updated to revenue of $473.3 million to $474.3 million and adjusted EBITDA of $224.5 million to $225.5 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Doximity filing is on SEC EDGAR ↗. 8-K briefs of other companies →